Filing Details
Vaxcyte, Inc. (NASDAQ:PCVX) filed a Form 8-K with the Securities and Exchange Commission on October 05, 2026, disclosing a material event.
8k filedNASDAQ:PCVX
Vaxcyte, Inc. (PCVX) Reports Material Event to SEC
Vaxcyte, Inc. (NASDAQ:PCVX) filed a Form 8-K with the Securities and Exchange Commission on October 05, 2026, disclosing a material event.
At publication ·
What changed
Vaxcyte, Inc. (NASDAQ:PCVX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Vaxcyte, Inc. filed a Form 8-K with the SEC on October 5, 2026, disclosing a material event requiring shareholder attention.
- The company's stock trades at $73.82 with a market capitalization of $5.8 billion.
- Form 8-K filings report significant events such as leadership changes, material agreements, acquisitions, or asset sales between regular reports.
Market Context
Vaxcyte, Inc.'s stock currently trades at $73.82 with a market capitalization of $5.8B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Vaxcyte, Inc.'s stock.
All SEC filings for Vaxcyte, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PCVX Stock Page
Frequently Asked Questions
Where can I read PCVX's SEC filings?
Browse all filings on our PCVX SEC filings page.
What types of SEC filings does Vaxcyte, Inc. file?
Public companies like Vaxcyte, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.